APP and Alzheimer disease: However, protein overexpression at much higher than physiological levels, such as APP transgenic mice which develop cerebral amyloidosis (Jacobsen et al., 2014; Neumann et al., 2015) may lead to negative results after compound administration perhaps not necessarily due to compound inefficacy but rather to forced protein expression levels much higher than in AD patients.